Geneprint combines genomics, blood-based biology, health history and AI to build a personalised cancer prevention and screening programme — delivered by your hospital.
AI analyses inherited, clinical and biological factors together.
Receive a screening plan based on your individual profile.
Understand which risks may be reduced or better managed.
Access results, actions and annual updates through one secure portal.
A trained health professional reviews your medical, family and screening history.
Several advanced analyses are performed from one blood-collection appointment.
Your genomics, blood-based biology and health information are analysed together.
You receive your Cancer Risk Map, screening programme, prevention priorities and next actions.
Inherited cancer risk, hereditary findings and selected polygenic risk.
Medical history, previous screening, family history and recognised risk factors.
Clinical biomarkers, plasma proteomics and metabolomics.
Screening results, new medical information and annual reassessment where appropriate.
Every Geneprint programme translates deep biological data into clear, clinically governed deliverables.
See everything includedOnly relevant cancers are assessed for each individual — this is an illustrative example, not a universal panel.
Main drivers: family history, breast density, hormonal factors.
Recommended: begin enhanced screening at 40.
Main drivers: age, standard population risk profile.
Recommended: routine screening from 45.
Main drivers: inherited variant, first-degree family history.
Recommended: specialist referral advised.
Insufficient validated data available for this profile.
Recommended: follow national guidance.
Main drivers: UV exposure history, skin type.
Recommended: annual dermatological review.
Main drivers: pathogenic germline variant identified.
Recommended: genetic counselling referral.
One venipuncture, several collection tubes, in a single appointment — supporting whole-genome sequencing, clinical laboratory testing, proteomics, metabolomics and additional eligible tests where appropriate.
AI supports the analysis. It never replaces clinical judgement.
Clinicians review important findings before any report is released.
Recommendations remain clinically governed at every step.
Results are explained in clear, patient-friendly language.
Geneprint is available only through approved partner hospitals — trained, certified, and equipped to manage every clinical step from consent to referral.
Programme available at
Every Geneprint Partner Hospital meets requirements for patient selection, consent, sample handling, data governance and specialist referral.
During your 12-month programme you can access your report and portal, review your screening plan, receive reminders, add new results, see updated actions and ask the AI assistant questions.
At the end of your 12-month programme, an optional reassessment may include updated history, reinterpretation of your genomic data, and — where recommended — one new blood draw and updated AI predictions.
Geneprint is a risk and prevention programme for healthy individuals — it is not a diagnostic pathway. If you have active or concerning symptoms, please contact your hospital directly for clinical assessment.